Elevation Oncology
Merus, Elevation Oncology Drugs Show Initial Activity in Lung, Pancreatic Cancers With NRG1 Fusions
Premium
The companies have pan-cancer ambitions for these drugs, and the data presented at ASCO are starting to show activity in specific NRG1 fusion-positive tumor types.
Genomic Testing Cooperative to ID Patients for Elevation Oncology's Seribantumab Trial
GTC will use its Solid Tumor Profile Plus test to identify solid cancer patients with NRG1 gene fusions for enrollment in Elevation's Phase II CRESTONE trial.
Elevation Oncology Prices $100M Initial Public Offering
Elevation will use the IPO proceeds to complete the Phase II CRESTONE trial of seribantumab in solid tumors with NRG1 fusions.
Caris Life Sciences, Elevation Oncology Team on Targeted Drug Development
The companies are working together to mine Caris' multiomic data for new cancer drug targets, sharing drug/diagnostic development costs for chosen candidates.